Drug Profile


Alternative Names: ALN-GO1

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Glycolate oxidase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Primary hyperoxaluria

Most Recent Events

  • 27 Sep 2016 Initial safety and efficacy data from phase I/II trial in Primary hyperoxaluria were released by Alnylam
  • 09 Mar 2016 Phase-I/II clinical trials in Primary hyperoxaluria (In children, In adolescents, In adults) in United Kingdom (SC)
  • 09 Mar 2016 ALN GO1 receives Orphan Drug status for Primary hyperoxaluria in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top